Koskinen P K, Lemström K B, Häyry P J
Transplantation Laboratory, University of Helsinki, Finland.
Am J Pathol. 1995 Apr;146(4):972-80.
Accelerated allograft arteriosclerosis (chronic rejection) has emerged as a major factor affecting long-term survival of human cardiac allografts. The underlying mechanism of this disorder remains unclear. The purpose of this study was to investigate the effect of cyclosporine on the development of cardiac allograft arteriosclerosis at the cellular and molecular level. Heterotopic rat cardiac allografts from DA donors to WF recipients, with a strong genetic disparity in major histocompatibility complex and non-major histocompatibility complex loci, were used. The allograft recipients received triple-drug immunosuppression consisting of methylprednisolone (0.5 mg/kg/day), azathioprine (2 mg/kg/day), and three different doses of cyclosporine A (CsA; 5, 10, and 20 mg/kg/day). The grafts were removed 3 months after transplantation and processed for histology and immunohistochemistry. Low dose CsA (5 mg/kg/day) was associated with a severe form of intimal cell accumulation and intimal thickening in epicardial arteries and in smaller intramyocardial arterioles with nearly occluded vessel lumens 3 months after transplantation. The intermediate dose CsA (10 mg/kg/day) significantly inhibited arterial intimal thickening but was not efficient in reducing intimal cell accumulation. Instead, high dose CsA (20 mg/kg/day) significantly inhibited all arteriosclerotic vascular wall changes in the allografts. Immunohistochemistry revealed that the occluded epicardial arteries of cardiac allografts with low dose CsA expressed VCAM-1 on the endothelium. Higher CsA doses significantly reduced the expression of endothelial VCAM-1. Neither ICAM-1 nor major histocompatibility complex class II were expressed. Perivascular arterial infiltrates consisting of T helper cells and monocytes/macrophages were a characteristic finding in the allograft with low dose CsA. In the allografts treated with higher doses of CsA, arterial perivascular infiltrates were seldom seen. Our results conclusively demonstrate that sufficient immunosuppression with CsA inhibits intimal thickening and intimal cell accumulation of long-surviving rat cardiac allografts in a dose-dependent fashion. Arteriosclerotic alterations associated with increased expression of arterial endothelial VCAM-1 were totally down-regulated by high doses of CsA.
加速性同种异体移植动脉硬化(慢性排斥反应)已成为影响人类心脏同种异体移植长期存活的主要因素。这种疾病的潜在机制仍不清楚。本研究的目的是在细胞和分子水平上研究环孢素对心脏同种异体移植动脉硬化发展的影响。使用了从DA供体到WF受体的异位大鼠心脏同种异体移植,在主要组织相容性复合体和非主要组织相容性复合体基因座上存在强烈的遗传差异。同种异体移植受体接受由甲基泼尼松龙(0.5mg/kg/天)、硫唑嘌呤(2mg/kg/天)和三种不同剂量的环孢素A(CsA;5、10和20mg/kg/天)组成的三联药物免疫抑制。移植后3个月取出移植物,进行组织学和免疫组织化学处理。低剂量CsA(5mg/kg/天)与移植后3个月时心外膜动脉和较小的心肌内小动脉中严重的内膜细胞积聚和内膜增厚有关,血管腔几乎闭塞。中等剂量CsA(10mg/kg/天)显著抑制动脉内膜增厚,但在减少内膜细胞积聚方面效果不佳。相反,高剂量CsA(20mg/kg/天)显著抑制同种异体移植物中所有动脉硬化性血管壁变化。免疫组织化学显示,低剂量CsA的心脏同种异体移植物中闭塞的心外膜动脉在内皮上表达血管细胞黏附分子-1(VCAM-1)。较高剂量的CsA显著降低内皮VCAM-1的表达。细胞间黏附分子-1(ICAM-1)和主要组织相容性复合体II类均未表达。由辅助性T细胞和单核细胞/巨噬细胞组成的血管周围动脉浸润是低剂量CsA同种异体移植物中的一个特征性发现。在用较高剂量CsA治疗的同种异体移植物中,很少见到血管周围动脉浸润。我们的结果确凿地表明,用CsA进行充分的免疫抑制以剂量依赖的方式抑制长期存活的大鼠心脏同种异体移植物的内膜增厚和内膜细胞积聚。与动脉内皮VCAM-1表达增加相关的动脉硬化改变被高剂量CsA完全下调。